Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.
Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.
复制标题
勘误表：在人体实验室研究中比较和结合托吡酯和阿立哌唑对酒精相关结果的影响。
DOI：
10.1093/alcalc/agy030
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Swift,RobertM
中科院分区：
文献类型：
--
作者：
Haass-Koffler,CarolinaL;Goodyear,Kimberly;Zywiak,WilliamH;Leggio,Lorenzo;Kenna,GeorgeA;Swift,RobertM
在我们的手稿中（Haass-Koffler et al.，2017），我们报告称，在4周滴定和1周目标剂量后，托吡酯在降低体重指数（BMI）方面具有显著的主效应。但是，我们没有具体说明BMI下降了多少。该信息对于报告非常重要，因为在人体实验室阶段，根据体内水分调整了自我给药酒精的量，并且计算部分基于体重。这一信息可能与托吡酯200 mg/天在自然阶段减少酒精消耗和减少酒精渴望的研究结果有关，但在人类实验室阶段没有。在第5周，托吡酯对BMI有显著的主效应[F1，37= 6.07，P= 0.019]，阿立哌唑作为协变量，与时间相互作用，参见统计方法的手稿（Haass-Koffler等人，2017年）。托吡酯组显示平均BMI降低0.36（0.16 SD），而未接受托吡酯的组（阿立哌唑和安慰剂）显示平均BMI增加0.32（0.22 SD）。只有当托吡酯剂量（100 mg和200 mg）为
In our manuscript (Haass-Koffler et al., 2017), we report that after 4 week titration and 1 week at target dose, there was a significant main effect for topiramate in decreasing body mass index (BMI). However, we did not specify how much BMIs declined. This information is important to report as the amount of the self-administered alcohol was adjusted based on body water during the human laboratory phase and the calculation is in part based on body weight. This information could be relevant to the study findings that topiramate 200mg/day reduced alcohol consumption and lessened alcohol craving in the naturalistic phase, but not in the human laboratory phase.At Week 5, there was a significant main effect for topiramate on BMI [F1, 37= 6.07, P= 0.019] with aripiprazole as covariate and interaction with time, see manuscript for statistical approach (Haass-Koffler et al., 2017). The topiramate group showed a mean BMI loss of 0.36 (0.16 SD) while groups not receiving topiramate (aripiprazole and placebo) showed a mean BMI gain of 0.32 (0.22 SD) from baseline. The significant reduction of BMI, was observed only when the topiramate doses (100 mg and 200 mg) were